<DOC>
	<DOCNO>NCT00902525</DOCNO>
	<brief_summary>Despite availability treatment disease , study justify know therapy really curative necessary look new treatment option improve clinical outcome prognosis relapse aggressive lymphoma . This study design patient eligible high-dose chemotherapy autologous stem cell transplantation .</brief_summary>
	<brief_title>Zevalin Twice Aggressive Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>The objective study evaluate efficacy safety two sequential dos 90Y-Ibritumomab Tiuxetan administer salvage chemotherapy patient relapsed/refractory aggressive lymphoma non-eligible HDC ASCT .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age 1875 2 . Diagnosis CD20+ Bdiffuse large cell de novo transform follicular lymphoma grade IIIb 3 . Stage II , III , IV accord Ann Arbor criteria 4 . Chemoresistant disease first line treatment ( CHOPlike + Rituximab ) relapse patient one two line chemotherapy noteligible high dose chemotherapy autologous stem cell transplantation 5 . Performance status 02 accord WHO criteria 6 . HIV negativity 7 . Normal liver , lung kidney function : conjugate bilirubin 2 x ULN , alkaline phosphatase transaminases 2 x ULN , creatinine clearance ≥45 ml/min 8 . Neutrophils count ³ 1.5 x 109/l , Haemoglobin ³ 9 g/dl , Platelets ³ 150 x 109/l bone marrow involvement &lt; 25 % first Zevalin infusion . 9 . Neutrophils count ³ 1.5 x 109/l , Haemoglobin ³ 9 g/dl , Platelets ³ 100 x 109/l second Zevalin infusion 10 . Use effective contraception entire treatment period patient sexually active 11 . Negative pregnancy test child bear potential woman 12 . Life expectancy &gt; 6 month 13 . Written inform consent 1 . More two line prior chemotherapy study entry 2 . Prior high dose chemotherapy autologous stem cell transplantation 3 . HIV positivity 4 . HBV positivity exception patient HBVcAb + , HbsAg , HBs Ab+/ HBVDNA negative 5 . HCV positivity exception patient sign active chronic hepatitis histologically confirm 6 . History clinically relevant liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , rheumatologic , hematologic , psychiatric , metabolic disturbance 7 . Uncontrolled diabetes ( receive antidiabetic agent , subject must stable dose least 3 month first dose study drug 8 . Uncontrolled severe cardiovascular disease include myocardial infarction within 6 month enrollment , New York Heart Association ( NYHA ) Class III IV heart failure ( Attachment 5 , NYHA Classification Cardiac Disease ) , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis 9 . Pregnant breastfeed 10 . CNS lymphoma involvement . 11 . History malignant carcinoma within last 3 year squamous cell basal cell carcinoma . 12 . Cardiac failure VEF &lt; 40 % 13 . Clinical evidence control infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>two sequential dos 90Y-Ibritumomab Tiuxetan</keyword>
</DOC>